Latin America's regulatory competition entered a new phase this week, with three major agencies moving aggressively to shorten timelines, increase transparency, and position
first-in-human · FIH · clinical trial · clinical research · regulatory · ANMAT
Latin America's regulatory competition entered a new phase this week, with three major agencies moving aggressively to shorten timelines, increase transparency, and position themselves for a larger share of global early-phase trials -- even as the EU formally launched its own monitoring program against a 2030 horizon.
Mexico's COFEPRIS targets a 45-to-30-day clinical trial authorization cycle via parallel modular review Argentina's ANMAT publishes the 2025 trial dataset establishing the empirical baseline for its 62-day cap Colombia's INVIMA releases a rare 2017-2024 transparency registry on non-approved device studies FDA's Real-Time Clinical Trial (RTCT) pilot RFI closes May 29 with AstraZeneca and Amgen confirmed Avance Clinical anchors ASCO 2026 oncology programming, signaling intensifying CRO competition The EU's 2030 clinical trial monitoring program reframes LATAM's 2026-2028 speed window
Take a closer look at how three LATAM regulators are pulling toward the same destination from different starting points. 👇
At AMIIF's Primera Cumbre de Investigacion Clinica, COFEPRIS Commissioner Rodrigo Bazua announced the agency is reorganizing internal processes to move from a 45-day to a 30-day clinical trial authorization target. The mechanism is structural rather than legislative: COFEPRIS is shifting from sequential review -- where a chemical evaluator and a medical evaluator process a dossier in series -- toward simultaneous, parallel modular review of the same submission.
If implemented successfully, the change would move Mexico from one of the slower major LATAM jurisdictions on FIH authorization into direct timeline competition with Colombia's INVIMA target and below Argentina's legislated 62-day cap.
Why It Matters: Process redesigns are harder to roll back than calendar promises. Sponsors evaluating Mexico for 2026-2027 filings should track operational signals -- not just the announced target -- to confirm that parallel review is producing measurable cycle-time reductions before committing.
Argentina published one of the clearest clinical research signals of the year with new ANMAT data covering 2025: 290 new clinical studies approved (an 8% year-over-year increase), more than 1,000 active investigations, and over 50,000 participants enrolled. Therapeutic distribution skewed heavily oncological, with oncology accounting for 25% of all approvals, followed by respiratory disease, immunology, metabolism, and central nervous system programs.
The data matters because it establishes the empirical baseline for Argentina's 62-day approval framework under Disposicion 7516/2025. While operational timeline data remains unpublished, the volume trend confirms sponsors are increasing engagement with the market before the cap is fully validated in practice.
Bottom Line: Argentina's regulatory story is no longer purely theoretical. The volume trend is now measurable, even if the 62-day metric is not.
INVIMA published a historical registry of non-approved medical device clinical studies covering 2017 through 2024 -- an unusually detailed look into regulatory outcomes and sponsor withdrawals in Colombia. The registry includes protocol titles, sponsors, investigators, IRBs, rejection or withdrawal reasons, and device categories spanning ophthalmology, robotic endoscopy, exoskeletons, stents, lumbar implants, and mechanical ventilators.
The strategic value is competitive intelligence. Sponsors can now begin analyzing which device categories face the highest rejection or withdrawal risk in Colombia -- a transparency level rarely available in LATAM regulatory systems. For device sponsors evaluating INVIMA, this may become one of the most operationally useful transparency releases in years.
What to Focus On: Device sponsors should commission a categorical analysis of the registry before drafting 2026 Colombian protocols. Rejection patterns visible in the dataset are likely to repeat unless protocols are structurally adapted.
bioaccess® is the world's First-in-Human CRO built for U.S. regulatory anchoring and Latin American execution. We help MedTech, Biopharma, and Radiopharma innovators compress timelines, reduce costs, and generate FDA/EMA-ready evidence -- across seven active LATAM jurisdictions.
40% faster regulatory approvals across Argentina, Brazil, Colombia, Mexico/Panama, Bolivia, Chile, and Costa Rica 30% lower clinical trial costs versus US and EU benchmarks End-to-end execution from feasibility through first patient in
Schedule your first-in-human trial consultation at bioaccessla.com.
The FDA's Request for Information for its Real-Time Clinical Trial (RTCT) pilot closes May 29, with pilot studies from AstraZeneca's TrAVeRse program and Amgen's STREAM-SCLC program already confirmed. The pilot is built around continuous data capture and near real-time regulatory visibility during ongoing trials -- a structural shift in how early-phase studies interact with reviewers.
For CROs and site networks operating in Latin America, the implication is direct: activation speed alone may no longer be enough. Data responsiveness and integration capability are becoming part of the competitive equation.
Why It Matters: LATAM site networks that have built early-phase speed advantages will need to layer real-time data infrastructure to remain eligible for RTCT-style programs as the model scales beyond the initial pilot.
Global CRO competition continued to intensify this week. Following Frost & Sullivan's 2026 Global Company of the Year recognition, Avance Clinical announced it will anchor oncology programming at ASCO 2026, reinforcing the importance of integrated early-phase delivery models spanning the United States, Asia-Pacific, and Europe.
In parallel, the European Commission, HMA, and EMA published the first monitoring report tied to the EU's 2030 clinical trial regulatory goals -- a structural reminder that regulatory modernization is now happening globally, not only in emerging markets. Global trial initiation patterns continue to shift, with the U.S. share of trial starts declining over the past decade and China's share expanding rapidly.
Bottom Line: Brazil, Argentina, Mexico, Panama, and Costa Rica are accelerating in parallel, but so are the EU and Asia. The 2026-2028 window may represent LATAM's most important opportunity to establish itself as a durable early-phase destination before larger systems fully adapt.
COFEPRIS is redesigning its review process structurally, not legislatively -- making the 30-day target more credible than past calendar promises ANMAT's 2025 dataset confirms Argentina is gaining sponsor share before the 62-day cap is empirically validated INVIMA's non-approval registry creates competitive intelligence for device sponsors that did not previously exist in LATAM FDA RTCT will require LATAM sites to layer data responsiveness on top of activation speed to remain eligible ASCO 2026 and the EU's 2030 monitoring program signal that LATAM's speed window is narrowing The 2026-2028 period is the most important strategic window for LATAM to establish durable early-phase leadership Three LATAM regulators are pulling toward the same destination from different starting points -- and sponsors should be filing accordingly
← All Global Trial Accelerators editions · Contact bioaccess®